Bio-Rad Laboratories' stock performance was compared against the Russell 2000 Index and HFRX Equity Hedge Index in September 2025.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bio-Rad Laboratories' stock performance was compared against the Russell 2000 Index and HFRX Equity Hedge Index in September 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bio-Rad Laboratories
American life science research firm
- Strategic acquisitions and product launches are driving growth for Bio-Rad Laboratories in the life science ddPCR and clinical diagnostics markets.
- Bio-Rad Laboratories is applying digital PCR technology through current partnerships, including Biodesix, Gencove, Insight Molecular, and Stilla Technologies.
Coverage
Newest first; wire copies grouped- Insider MonkeyIs Bio-Rad Laboratories (BIO) Entering a Period of More Sustained Recovery? Prosper Stars & Stripes, a long/short equity fund, recently released its second quarter 2025 investor letter. A copy of the